Contributors to satisfaction with combined drug and behavioral therapy for overactive bladder in subjects dissatisfied with prior drug treatment

Journal of Wound, Ostomy and Continence Nursing

Volumn 37, Issue 2, 2010, Pages 199-205

  Wyman, Jean F ^a   Harding, Gale ^b   Klutke, Carl ^c   Burgio, Kathryn ^d   Berriman, Sandra ^e   Vats, Vasudha ^f   Bavendam, Tamara ^f   Coyne, Karin S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e Phizer Inc   (United States)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE; TOLTERODINE;

ARTICLE; BEHAVIOR THERAPY; FEMALE; HUMAN; INTERVIEW; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERACTIVE BLADDER; PATIENT SATISFACTION;

BEHAVIOR THERAPY; BENZHYDRYL COMPOUNDS; COMBINED MODALITY THERAPY; CRESOLS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; URINARY BLADDER, OVERACTIVE;

EID: 77949549753     PISSN: 10715754     EISSN: None     Source Type: Journal    
DOI: 10.1097/WON.0b013e3181cf722f     Document Type: Article

References (27)

1. Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn. 2006;25:293.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-336.
3. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61:1123-1128.
4. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455-463.
5. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388-1395.
6. Andersson K-E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004;3:46-53.
7. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543-562.
8. Milne JL. Behavioral therapies for overactive bladder: making sense of the evidence. J Wound Ostomy Continence Nurs. 2008; 35:93-101.
9. Burgio KL. Behavioral treatment options for urinary incontinence. Gastroenterology. 2004;126:S82-S89.
10. Wyman JF, Fantl JA, McClish DK, Bump RC. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol. 1998;179:999-1007.
11. Burgio KL. Current perspectives on management of urgency using bladder and behavioral training. J Am Acad Nurse Pract. 2004;16:4-7.
12. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48:370-374.
13. Mattiasson A, Blaakaer J, Hoye K, Wein AJ. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91:54-60.
14. Klutke CG, Burgio KL, Wyman JF, et al. Combined effects of behavioral intervention and tolterodine in subjects dissatisfied with their overactive bladder medication. J Urol. 2009;181:2599-2607.
15. Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology. 2006;68:9-16.
16. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49:1079-1086.
17. Pleil AM, Coyne KS, Reese PR, et al. The validation of patientrated global assessments of treatment benefit, satisfaction, and willingness to continue-the BSW. Value Health. 2005;8:S25-S34.
18. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320:114-116.
19. Polit DF, Hungler BP. Nursing Research: Principles and Methods. Philadelphia, PA: JB Lippincott Co; 1995.
20. Newman DK. Report of a mail survey of women with bladder control disorders. Urol Nurs. 2004;24:499-507.
21. Nicolson P, Kopp Z, Chapple CR, Kelleher C. It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol. 2008;13:343-359.
22. DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients' perspective and explanatory style. J Am Geriatr Soc. 1998;46:683-692.
23. Rodriguez LV, Blander DS, Dorey F, Raz S, Zimmern P. Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms. Urology. 2003;62:49-53.
24. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health. 2005; 8:495-505.
25. Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface. 2004;17:54-60.
26. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care. 2005;11:S121-S129.
27. Herschorn S, Becker D, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol. 2004;11:2430-2437.